Table 1.

Knockout mice of ARF and INK4a

	Strain	Targeting site	Treatment	Type of tumor formation	Latency	Ref
ARF−/−	129svj X C57BL6	Exon1β	None	Sarcoma (43%) Lymphoid malignancies (29%) Carcinoma (17%) /Squamous cell carcinoma /Pulmonary adenocarcinoma /Poorly differentiated carcinoma in pancreas /Salivary gland carcinoma Tumors of the nervous system (11%) /Spinal cord neural sheath tumor/Glioma	~38 weeks	56
			DMBA	Squamous cell carcinoma /+Lymphoma /+Sarcoma and adnexal tumor /+Sarcoma and lymphomax /+sarcoma	~24 weeks
			X-ray	Sarcomas Lymphoma Meningeal tumor
ARF−/−	FVB	Exon1β	None	Small lymphoma (33%) Malig. Sp. Cell neo (30%) Lung carcinoma (12%) Osteogenic sarcoma (9%) Tumors of the nervous system (9%) Carcinoma/HCC (6%)	~62 weeks	57
			DMBA	Small lymphoma (60%) Malig. Sp. Cell neo (40%) Lung carcinoma (15%)	~24 weeks
ARF−/−	C57Bl/6	Exon1β	None	Fibrosarcoma (33.3%) Metastatic salivary gland carcinoma (16.7%) Thymoma (16.7%) Malignant fibrous histocytoma (16.7%) Lymphoma (brain) (16.7%)	~21 weeks	58
			DMBA	Epidermal papilloma (55.5%) Lymphoma, Epidermal papilloma Fibrosarcoma, malignant adenexal tumor Fibrosarcoma, epidermal papilloma Invasive epidermoid carcinoma	~20 weeks
			Irradiation	Fibrosarcoma (50%) Lymphoma (brain) (50%)	~19 weeks
INK4a−/−	FVB	Exon1α	None	Soft-tissue sarcoma (12.8%) Splenic lymphoma (10.25%) Melanoma (2.56%)	~44 weeks	59
			DMBA	Thymic lymphoma (13%) Splenic lymphoma (6%) Soft-tissue sarcoma (10%) Malignant spindle-cell neoplasma (6%) Lung adenoma (6%) Squamous papilloma (29%)	~23 weeks
INK4a−/−, ARF−/−	C57BL/6	Exon2, 3	None	Fibrosarcoma (33.3%) Sarcoma Liposarcoma, Lyphoma Angiosarcoma B-cell lymphoma Lymphoma	~36 weeks	55
			UV	Fibrosarcoma (50%) Squamous cell carcinoma Lymphoma	~36 weeks
			DMBA+UV	Fibrosarcoma (50%) B-cell lymphoma Lymphoma Low grade Fibrosarcoma Squamous cell carcinoma	~14 weeks